

REMARKS

I. Status of the Claims

Applicants thank the Examiner for allowing claims 50 and 54-65. Claim 72 is objected to as being dependent on a rejected claim. New claims 73 and 74 are added. New claims are supported, for example, by Example 20 of the specification, and thus do not constitute new matter. Claims 1-49, 51-53 and 66-72 have been canceled without disclaimer or prejudice. Applicants hereby explicitly reserve the right to prosecute the canceled subject matter in one or more future applications.

II. Claim Rejections under 35 U.S.C. § 102

Claims 66-71 stand rejected under 35 U.S.C. § 102(b) over Sherr et al. (U.S. Patent No. 6,407,062). Specifically, the Action asserts that the Sherr reference discloses a method of preventing abnormal cell growth in a mammalian cell comprising administering a composition comprising a peptide having a sequence that purportedly overlaps with SEQ ID NO:10. Applicants respectfully traverse the rejection but have nevertheless canceled the claims. Thus, the rejection has now become moot.

III. Conclusions

Applicants respectfully submit that all conditions of patentability are satisfied in the pending claims. Allowance of the claims is thereby respectfully solicited.

The Examiner in charge of this application is invited to contact the undersigned representative as indicated below if it is believed to be helpful.

Respectfully submitted,

Dated: May 17, 2009

By: /Y. Elaine Chang/
Yijan Elaine Chang
Reg. No. 54,698

McDonnell Boehnen Hulbert & Berghoff LLP

300 South Wacker Drive, Ste 3100

Chicago, IL 60606

Telephone: (312) 913-0001

Facsimile: (312) 913-0002